P01HL173579
Project Grant
Overview
Grant Description
The New Zimmerman Program for the Genetics and Biology of von Willebrand Factor and von Willebrand Disease - Project Summary:
Overall this Program Project Grant (PPG) aims to address important gaps in knowledge concerning the genetic, molecular and biologic control of von Willebrand Factor (VWF) and pathogenesis of von Willebrand Disease (VWD).
The PPG consists of 4 projects and 3 cores that all focus on VWF and mechanisms influencing its genetic regulation, expression, dysfunction, increased clearance, interactions with FVIII and the role of carbohydrate modification in VWF biology.
While this is a new PPG application, this program has access to tens of thousands of samples and extensive biodata from the pre-existing PPG, the Zimmerman Program.
Project 1 will focus on resolving, by identifying common and rare variants, including complex loci, the condition called low von Willebrand Factor; the 20-25% increase in VWF levels seen in individuals from African ancestry; and the increase in VWF levels observed with aging.
Cohorts of subjects with low VWF, with no sequence variants in VWF will undergo whole genome and long read sequencing.
Whole genome sequencing of multiple multiethnic cohorts will allow for admixture studies that will leverage the power of trans-ethnic fine mapping and haplotype association.
In active collaboration with Project 1, Project 2 will assemble and analyze one of the largest collections of phenotypic, genomic, and multi-tissue transcriptomic, proteomic and other -omics data to identify molecular signatures of low-VWF/VWD that will lead to novel insights into pathways associated with disease etiology.
Project 2 will analyze human multi-omic data in large and well-characterized cohorts and shed additional light on the pathological events that lead to low-VWF/VWD and to age-dependent changes in VWF.
With these discoveries, we will generate polygenic risk scores for low VWF and VWD.
Project 3 will investigate distinct features of how and where VWF and FVIII are expressed; whether an intracellular chaperone effect of VWF can reduce the cellular stress associated with FVIII expression, and will characterize the influence of VWF on the clearance and subsequent immunogenic nature of FVIII.
Project 4 will focus on the role of glycans in VWF biology and will investigate the roles that N and O glycans play in VWF biosynthesis, characterize glycans involvement in VWF activation and define the impact of glycans in regulating VWF clearance pathways.
Core A is the administrative core that will facilitate communication between the centers involved in this multi-institutional PPG, and will provide all administrative oversight.
Core B is the bioinformatics core and the site for all genome and mass spec -omics studies involved in this PPG.
In addition, Core B will operate the Zimmerman Analytical Platform, our secure web-based interface, developed to oversee the exchange of multiomics data, patient samples and biodata on the Velos database in Core C.
Core C is the PPG biorepository and central laboratory that will oversee the distribution of approximately 95,000 samples from 7,000 individuals to the different projects and will coordinate the recruitment of 7 primary clinical centers that will be following our enrolled subjects.
Together these studies will comprehensively study novel aspects of VWF biology and pathobiology, and will shed new light on the pathogenesis of VWD.
Overall this Program Project Grant (PPG) aims to address important gaps in knowledge concerning the genetic, molecular and biologic control of von Willebrand Factor (VWF) and pathogenesis of von Willebrand Disease (VWD).
The PPG consists of 4 projects and 3 cores that all focus on VWF and mechanisms influencing its genetic regulation, expression, dysfunction, increased clearance, interactions with FVIII and the role of carbohydrate modification in VWF biology.
While this is a new PPG application, this program has access to tens of thousands of samples and extensive biodata from the pre-existing PPG, the Zimmerman Program.
Project 1 will focus on resolving, by identifying common and rare variants, including complex loci, the condition called low von Willebrand Factor; the 20-25% increase in VWF levels seen in individuals from African ancestry; and the increase in VWF levels observed with aging.
Cohorts of subjects with low VWF, with no sequence variants in VWF will undergo whole genome and long read sequencing.
Whole genome sequencing of multiple multiethnic cohorts will allow for admixture studies that will leverage the power of trans-ethnic fine mapping and haplotype association.
In active collaboration with Project 1, Project 2 will assemble and analyze one of the largest collections of phenotypic, genomic, and multi-tissue transcriptomic, proteomic and other -omics data to identify molecular signatures of low-VWF/VWD that will lead to novel insights into pathways associated with disease etiology.
Project 2 will analyze human multi-omic data in large and well-characterized cohorts and shed additional light on the pathological events that lead to low-VWF/VWD and to age-dependent changes in VWF.
With these discoveries, we will generate polygenic risk scores for low VWF and VWD.
Project 3 will investigate distinct features of how and where VWF and FVIII are expressed; whether an intracellular chaperone effect of VWF can reduce the cellular stress associated with FVIII expression, and will characterize the influence of VWF on the clearance and subsequent immunogenic nature of FVIII.
Project 4 will focus on the role of glycans in VWF biology and will investigate the roles that N and O glycans play in VWF biosynthesis, characterize glycans involvement in VWF activation and define the impact of glycans in regulating VWF clearance pathways.
Core A is the administrative core that will facilitate communication between the centers involved in this multi-institutional PPG, and will provide all administrative oversight.
Core B is the bioinformatics core and the site for all genome and mass spec -omics studies involved in this PPG.
In addition, Core B will operate the Zimmerman Analytical Platform, our secure web-based interface, developed to oversee the exchange of multiomics data, patient samples and biodata on the Velos database in Core C.
Core C is the PPG biorepository and central laboratory that will oversee the distribution of approximately 95,000 samples from 7,000 individuals to the different projects and will coordinate the recruitment of 7 primary clinical centers that will be following our enrolled subjects.
Together these studies will comprehensively study novel aspects of VWF biology and pathobiology, and will shed new light on the pathogenesis of VWD.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Saint Louis,
Missouri
631101010
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 94% from $2,363,224 to $4,573,035.
Washington University was awarded
Genetics and Biology of von Willebrand Factor: Advancing VWD Research
Project Grant P01HL173579
worth $4,573,035
from National Heart Lung and Blood Institute in May 2025 with work to be completed primarily in Saint Louis Missouri United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.837 Cardiovascular Diseases Research.
The Project Grant was awarded through grant opportunity NHLBI Program Project Applications (P01 Clinical Trials Optional).
Status
(Ongoing)
Last Modified 6/5/26
Period of Performance
5/15/25
Start Date
4/30/30
End Date
Funding Split
$4.6M
Federal Obligation
$0.0
Non-Federal Obligation
$4.6M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for P01HL173579
Transaction History
Modifications to P01HL173579
Additional Detail
Award ID FAIN
P01HL173579
SAI Number
P01HL173579-2060959889
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Funding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Awardee UEI
L6NFUM28LQM5
Awardee CAGE
2B003
Performance District
MO-01
Senators
Joshua Hawley
Eric Schmitt
Eric Schmitt
Modified: 6/5/26